Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 5—May 2021
Dispatch

Evaluating Differences in Whole Blood, Serum, and Urine Screening Tests for Zika Virus, Puerto Rico, USA, 2016

Asher Y. Rosinger1, Samantha M. Olson1Comments to Author , Sascha R. Ellington, Janice Perez-Padilla, Regina M. Simeone, Caitlin S. Pedati, Betsy A. Schroeder, Gilberto A. Santiago, Freddy A. Medina, Jorge L. Muñoz-Jordán, Laura E. Adams, Romeo R. Galang, Miguel Valencia-Prado, Sonia Bakkour, Candimar Colón, Mary Goodwin, Dana Meaney-Delman, Jennifer S. Read, Lyle R. Petersen, Denise J. Jamieson, Carmen C. Deseda, Margaret A. Honein, Brenda Rivera-García, and Carrie K. Shapiro-Mendoza
Author affiliations: The Pennsylvania State University, State College, Pennsylvania, USA (A.Y. Rosinger); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.Y. Rosinger, S.M. Olson, S.R. Ellington, R.M. Simeone, C.S. Pedati, B.A. Schroeder, R.R. Galang, M. Goodwin, D. Meaney-Delman, D.J. Jamieson, M.A. Honein, C.K. Shapiro-Mendoza); G2S Corporation, San Antonio, Texas, USA (S.M. Olson); Centers for Disease Control and Prevention, San Juan, Puerto Rico, USA (J. Perez-Padilla, G.A. Santiago, F.A. Medina, J.L. Muñoz-Jordán, L.E. Adams, C. Colón, J.S. Read); Iowa Department of Public Health, Des Moines, Iowa, USA (C.S. Pedati); Pennsylvania Department of Health, Harrisburg, Pennsylvania, USA (B.A. Schroeder); Puerto Rico Department of Health, San Juan (M. Valencia-Prado, C.C. Deseda, B. Rivera-García); Vitalant Research Institute, San Francisco, California, USA (S. Bakkour); University of Vermont Medical Center and Vermont Department of Health, Burlington, Vermont, USA (J.S. Read); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (L.R. Petersen); Emory University School of Medicine, Atlanta (D.J. Jamieson)

Main Article

Table 2

Number of positive tests for Zika virus among 514 asymptomatic pregnant women tested by specimen type and assay, Puerto Rico, USA, October 1–November 4, 2016*

Category
 NAAT
IgM
No. positive tests/no. tested (%)
 Median Ct value (range)
 No. positive tests/no. tested (%)
Specimen type
Serum 20/509† (4) 37.2 (29.8–37.9) 45/508‡ (9)
Urine 10/503§ (2) 37.4 (36.2–37.9)
Whole blood
 8/507¶ (2)
 34.2 (29.8–36.7)
Total positive tests among pregnant women by test type#
 28/514 (5)
45/508 (9)
Total positive tests among pregnant women by any test or specimen type# 69/514 (13)

*Ct values were not compared across specimen types. IgM was performed only on serum specimens. Ct, cycle threshold; NAAT, nucleic acid amplification testing.
†5 serum specimens from asymptomatic women were unable to be provided for Trioplex NAAT.
‡6 serum specimens from asymptomatic women were unable to be provided or were inconclusive for Zika virus IgM testing.
§11 urine specimens from asymptomatic women were unable to be provided for Trioplex NAAT.
¶7 whole blood specimens for asymptomatic women were unable to be provided for Trioplex NAAT.
#The denominator includes pregnant women who were missing a test type.

Main Article

1These authors contributed equally to this article.

Page created: March 18, 2021
Page updated: April 21, 2021
Page reviewed: April 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external